Company intelligence / Profile preview
POP Biotechnologies
Buffalo, New York, United Statespop.bio ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Phase 3
01
Overview
POP Biotechnologies' lead vaccine candidate, EuCorVac‑19—a protein subunit COVID‑19 vaccine using the SNAP platform—met primary endpoints in a Phase 3 clinical trial in the Philippines. The company is also advancing RSV and shingles vaccine candidates into early clinical development. Its PoP liposome technology is being explored for targeted chemophototherapy of cancers. The company has received significant SBIR funding for influenza vaccine development and was recently accepted into the NCI Nanotechnology Characterization Program for its cancer vaccine concept.[1][4]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Liposome-based vaccines and therapeuticsNanoparticle drug delivery systemsTherapeutic vaccines (protein-based, peptide-based)Chemophototherapy (light-targeted chemotherapy)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
EuBiologics (co-development of EuCorVac–19)[6]Korea Institute of Science and Technology/EulMT licensee [2]
Beyond the preview
Go deeper on POP Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on POP Biotechnologies.